

RX-3117

Catalog No: tcsc3947



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

865838-26-2

Formula:

$C_{10}H_{12}FN_3O_4$

Pathway:

Cell Cycle/DNA Damage

Target:

Nucleoside Antimetabolite/Analog

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (194.39 mM)

Alternative Names:

TV-1360;fluorocyclopentenylcytosine

Observed Molecular Weight:

257.22

Product Description


RX-3117(TV-1360; Fluorocyclopentenylcytosine) is novel a cytidine analog; shows anticancer activity in several cancer cell lines, including gemcitabine-resistant variants.

IC50 value: 0.4- >30 nM (15 cancer cell lines) [1]

Target: cytidine analog

in vitro: RX-3117 showed a different sensitivity profile compared to cyclopentenyl-cytosine (CPEC) and azacytidine, substrates for uridine-cytidine-kinase (UCK).RX-3117 was a very poor substrate for cytidine deaminase (66,000-fold less than gemcitabine). In sensitive U937 cells 1 μ M RX-3117 resulted in 90% inhibition of RNA synthesis but 100 μ M RX-3117 was required in A2780 and CCRF-CEM cells. RX-3117 at IC50 values did not affect the integrity of RNA [1].

in vivo: Orally-administered RX-3117 was examined in 9 different human tumor xenograft models (colon, non-small cell lung, small cell lung, pancreatic, renal and cervical), grown subcutaneously in athymic nude mice. In the Colo 205, H460, H69 and CaSki models, gemcitabine treatment resulted in 28%, 30%, 25% and 0% tumor growth inhibition (TGI), respectively, whereas oral treatment with RX-3117 induced 100%, 78%, 62% and 66% TGI, respectively [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!